Approved for use through 02/29/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)

Shoet of.

Complete if Known				
Application Number	10/591,195			
Filing Date	September 29, 2006			
First Named Inventor	Liat Hayardeny			
Art Unit	1649			
Examiner Name	Kolker, Daniel E.			
Altomey Docket Number	68051-B-PCT-US/IPW			

	U. S. PATENT DOCUMENTS							
Examiner Initials*	No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant			
		Number-Kind Code <sup>2</sup> If Annual			Figures Appear			
/D.K./	1	<sup>US-</sup> 5,800,808	09-01-1998	Konfino, et al.				
1	2	<sup>US-</sup> 5,981,589	11-09-1999	Konfino, et al.				
	3	US- 6,048,898	04-11-2000	Konfino, et al.				
	4	US: 6,054,430	04-25-2000	Konfino, et al.				
	5	<sup>US-</sup> 6,214,791	04-10-2001	Amon, et al.				
	6	<sup>US-</sup> 6,342,476	01-29-2002	Konfino, et al.				
	7	US- 6,362,161	03-26-2002	Konfino, et al.				
	8	US- 6,514,938	02-04-2003	Gad, et al.				
	9	<sup>US-</sup> 6,620,847	09-16-2003	Konfino, et al.				
	10	<sup>US-</sup> 6,800,285	10-05-2004	Rodriguez				
	11	<sup>US-</sup> 6,800,287	10-05-2004	Gad, et al.				
	12	<sup>US-</sup> 6,939,539	09-06-2005	Konfino, et al.				
	13	<sup>US-</sup> 7,022,663	04-042006	Gilbert, et al.				
	14	<sup>US-</sup> 7,033,582	04-25-2006	Yong, et al.				
	15	us- 7,074,580	07-22-2006	Gad, et al.				
	16	<sup>US-</sup> 7,163,802 B2	01-16-2007	Gad, et al.				
	17	<sup>US-</sup> 7,199,098	04-03-2007	Konfino, et al.				
1/	18	<sup>US-</sup> 7,279,172	10-09-2007	Aharoni, et al.				
V	19	<sup>US-</sup> 2003-0170729 A1	09-11-2003	Klinger				

Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	1
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>5</sup> (# known)	MM-DD-YYYY	Approximent of Cited Document	Or Relevant Figures Appear	T <sup>6</sup>
/D.K./	29	WO 98/30227	07-16-1998	Yeda Research and Developme	ent CO., LTD.	
	30	WO 00/05250	02-03-2000	Yeda Research and Developme	ent CO., LTD.	
	31	WO 00/18794	04-06-2000	Yeda Research and Developm	ent CO., LTD.	Г
	32	WO 00/27417	05-18-2000	Yeda Research and Developme	ent CO., LTD.	-
	33	WO 01/60392	08-23-2001	Yeda Research and Developm	ent CO., LTD.	
_V_	34	WO 01/93828	12-13-2001	Teva Pharmaceuticals Industri	es, LTD.	

Examiner Signature Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (originate). \*See Kinds Codes of USPTO Petant Draumants at www.setgloog.get or MPEP 901-04. \*Einer Originate in the document, by the whether code (WIPO Standard ST-3). \*To Juaneses patient documents, his indication of the year of the resp. of the Emperor must precede the search anumber of the patient document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST-16 if possible. \*Applicant is to place a check mark here if English language Translation is attached

Institution is attached.

Institution is required by 37 CFR 1.07 and 1.98. The Information is required to a beautiful by the public visible is 56 (and by the USFTO is process) an application. Confidentiality is gowered by 39 USF. C.12 and 37 CFR 1.14. This confidentiality is polar to compete including patheting, preparing, and submitting life completed application form to the USFTO. Then will vary depending upon the individual case. Any comments including patheting, preparing, and submitting life completed application for the Central Information Officer, U.S. Patent and Tasteman Officer, P. O. Box 1450, Assentatio, V.A. 2213-1450, D.O. VERFORD FEED on COMPATED FEED of COMPATED FEED FEED OF COMPATED FEED FEED OF COMPATED FEED

ExhibitA

PTO/SB/08A (01-08) Approved for use through 02/29/2008, OMB 0651-0031

U.S. Palunt and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a culter-time of information unless of containing a valid OMB centrel number.

Substitute for form 144/MPTO

Complete if Known

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known				
Application Number	10/591,195			
Filing Date	September 29, 2006			
First Named Inventor	Liat Hayardeny			
Art Unit	1649			
Examiner Name	Kolker, Daniel E.			
Attorney Docket Number	68051-B-PCT-US/JPW			

	,	· · · · · · · · · · · · · · · · · · ·		T DOCUMENTS	
Examiner Initials*	No.1	Number-Kind Code <sup>*</sup> (Fanse)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/D.K./	20	US- 2005-0170004	08-04-2005	Rosenberger	
1	21	US- 2006-0122113	06-08-2006	Pinchasi, et at.	
$\neg$	22	US- 2006-0172942 A1	08-03-2006	Dolitzky	
	23	<sup>US-</sup> 2006-0052586	03-09-2006	Dolitzky	
	24	US- 2007-0021341 A1	01-25-2007	Seta, et al.	
	25	US- 2007-0021324 A1	01-25-2007	Dolitzky, et al.	
	26	US- 2007-0048794 A1	03-01-2007	Gad, et al.	
	27	<sup>US-</sup> 2007-0054857	03-08-2007	Pinchasi, et al.	
V	28	<sup>US-</sup> 11/590,338	10-30-2006	Pinchasi, et al.	
		US-			

		FORE	GN PATENT DOCU	MENTS		
Examiner Cite		Cite Foreign Patent Document Publication	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	Т
		Country Code * Number * 'Kind Code's (d known)	MM-DD-YYYY		Or Relevant Figures Appear	1
/D.K	/35	WO 01/97846	12-27-2001	Teva Pharmaceuticals Industri	es, LTD.	
1	36	WO 03/048735	06-12-2003	Teva Pharmaceuticals Industri	es, LTD.	Т
100	59	WO 04/43995	05-27-2004	APOTEX PHARMACHEN	INC.	Г
	60	WO 06/50122	05-11-2006	Sandoz AG		Г
V		WO 08/06026	01-10-2008	MOMENTA PHARMACE	UTICALS, INC.	Г
V 1	22.0					Г

Examiner Signature Considered

"EXAMMER! Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of the form with next communication to applicant. \*Applicant's uneque citation designation number (optional). \*See kinds Codes of USPTO Plantin Documents at www.apeclago.goz or MPEP 901.04. \*Finar (notion that leaves the document, by the worker code (MPEP Standard ST.3). \*For Juliant seeps patient documents, his noticition of the year of the regin of the Emperor must precise the sentil number of the patient document. \*Kind of document by the complex set of the communication of the document or more YMPO Standard ST.16 if possible. \*Applicant is to place a check must held reginsh tanguages.

Translation is altached.
The sciencion of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to fire (and by the USPTO) is process) an application. Confidentialist is governed by 35 U.S.C. 122 and 37 CFR 1.14. The collection is estimated to take 2 hours to compete, in the compete in the

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (01.08)

Approved for use through 02/29/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO	Complete if Known				
A STATE OF THE STA	Application Number	10/591,195			
INFORMATION DISCLOSURE	Filing Date	September 29, 2006			
STATEMENT BY APPLICANT	First Named Inventor	Liat Hayardeny			
(Use as many sheets as necessary)	Art Unit	1649			
(ost as many shorts as necessary)	Examiner Name	Kolker, Daniel E.			
Sheet 3 of 5	Attorney Docket Number	68051-B-PCT-US/JPW			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/D.K./	37	Bornstein et al., "Treatment of MS with a Synthetic Polypeptide: Preliminary Results" Ann. Neurol., 1980, 8, 117 ABSTRACT	
'D.K./	38	Bornstein et al., "Treatment of MS with synthetic polypeptide: preliminary results" Trans. Am. Neurol. Assoc., 1980, 105, 348-350	
/D.K./	39	Bornstein et al., "MS: Trial of a synthetic polypeptide" Ann. Neurol., 1982, 11, 317-319	
/D.K./	40	Bornstein et al., "Clinical trials of Copolymer 1 in MS" Ann. N.Y. Acad. Sci. (USA), 1984, 366-372	
/D.K./	41	Bornstein et al., "Clinical Trials of a synthetic polypeptide (Copolymer 1) for the treatment of MS" Immunol. & Clin. Aspects of MS, 1984, 144-150	
/D.K./	42	Bornstein et al., "MS: Clinical Trials of a Synthetic Polypeptide, Copolymer 1" Neurol., 1985, 35 (Suppl. 1), 103 ABSTRACT	
/D.K./	43	Bornstein, "Cop 1 may be beneficial for patients with exacerbating remitting form of MS" Adv. Ther., 1987, 4, 206 ABSTRACT	
/D.K./	44	Bornstein, et al., "A Pilot trial of Cop 1 in Exacerbating remitting MS" New Eng. J. Med., 1987, 317 (7), 408-414	
/D.K./	45	Bornstein, et al., "Clinical Experience with COP-1 in MS" Neurol., 1988, 38 (Suppl. 2.), 66-69	
	46	Bornstein, et al., "Flationate for Immunomodulating Therapies of MS" Neurol.,	
	-46	1088, 38 (Suppl. 2.), 80-81P.	

Examiner	Date
Signature	Considered
CVALUED, Initial II of the second of the sec	the state of the s

Signification:

EXAMMENT: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with need communication to applicant.

EXAMMENT: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation in not in conformance and not considered. Include copy in the proper service and t Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 02/29/2008, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO		Complete if Known			
	Application Number	10/591,195			
INFORMATION DISCLOSU	RE Filling Date	September 29, 2006			
STATEMENT BY APPLICA	NT First Named Inventor	Liat Hayardeny			
(Use as many sheets as necessary)	Art Unit	1649			
(032 23 11111) 311013 23 1102033219)	Examiner Name	Kolker, Daniel E.			
Sheet 4 of 5	Attorney Docket Number	68051-B-PCT-US/JPW			

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
/D.K./	47	Bornstein et al., "Pilot Trial of COP-1 in Chronic Progressive MS: Preliminary report" Intl. MS Conf.1988, in Elsevier Sci. Publi. 1989, 225-232	
/D.K./	48	Bornstein et al., "Clinical Trials of Cop 1 in MS" Handbook of MS, 1990, 469-480	
/D.K./	49	Bornstein et al., "A Placebo-controlled, Double-Blind, Randomized Two-center, Pilot Trial of Cop 1 in Chronic Progressive MS" Neurol., 1991, 41, 533-539	
	50	Domstein et al., "Treatment of MS with Copolymer 1" Treatmt. of MS, Trial	
/D.K./	51	Bornstein, "Clinical Experience: Hopeful Prospects in MS," Hosp Prac. (Off. Ed.) May 15, 1992 vol. 27 (No. 5) L135-138, 141-142, 145-158	
/D.K./	52	Kalkers et al "The effect of the neuroprotective agent riluzole on MRI perameters in primary progressive multiple sclerosis: a pilot study in Multiple Sclerosis. 2002. vol. 8, issue 6, pages 532-533	
/D.K./	53	Sela et al., "Glatiramer acetate in the treatment of multiple sclerosis" in Expert Opin. Pharmacother., 2001, vol.2, no.7, pages 1149-1165	2.25*****
/D.K./	54	Copaxone® (glatiramer acetate injection), prescribing information, http://www.copaxone.com/pdf/PrescribingInformation.pdf No date	
/D.K./	55	International Preliminary Report on Patentability issued by the International Bureau of WIFO dated December 24, 2007 in connection with International Application No. PCT/US2005/0007072	
/D.K./	56	PCT International Search Report issued November 30, 2007 for International Application Publication No. PCT/US2005/0007072	

Examiner	Date	
Signature	Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

EXAMINER: nitial if referrince considered, whether or not clation is all conformance with MPEP 659. Draw line through citation in conformance and not considered. Include copy of this form with next communication to applicant.

I Applicant's unique clution designation number (colorial), 2 Applicant is to place a check much here if English language Transistion is to file find by the USPTO in the content of the Colorial in the USPTO. The will vary depending upon the individual case. Any comments on the amount of time by unequire to complete this form and/or suggestions for election that both colorial in the Colorial i

PTO/SB/08B (01-08)

Approved for use through 02/29/2008. OMB 0851-0031 U.S. Patent and Trademerk Office; U.S. DEPARTMENT OF COMMERCE

Substitut	e for form 1449/PTO			Complete if Known			
(	- 10 10 11 11 10 1			Application Number	10/591,195		
INFO	DRMATION	I DIS	CLOSURE	Filing Date	September 29, 2006		
STATEMENT BY APPLICANT				First Named Inventor	Liat Hayardeny		
	//			Art Unit	1649	_	
(Use as many sheets as necessary)				Examiner Name	Kolker, Daniel E.		
Sheet	5	of	5	Attorney Docket Number	68051-B-PCT-US/JPW	7	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, citly and/or country where published.	T <sup>2</sup>
/D.K./	57	Written Opinion of the International Searching Authority issued by the International Searching Authority (ISA/AU) on November30,2007 in connection with International Application No. PCT/US2005/0007072	
/D.K./	58	*COPAXONE®* in Physician's Desk Reference, Medical Economics Co., Inc., Montvale, NJ, 2002, 3115 –3118	

Signature EXAMINER: I	nital if reference considered, whether or not citation is in conformance with MPEP 60	Considered		
Examiner	/Daniel Kolker/	Date	08/18/2008	l

considered. Include copy of this form with next communication to applicant.

Commissioner of Potents, P.O. Dos v1450, Alexandria, V2 2213-1450. DO NOT SEND FEED OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Dos v1450, Alexandria, V2 2231-1450. DO NOT SEND FEED OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: